Overview
- Nature published studies detailing DeepMind’s Co-Scientist and FutureHouse/Edison’s Robin, agent systems that read papers, form hypotheses, and plan experiments to speed research.
- Edison announced a collaboration with Incyte to deploy its larger platform, Kosmos, across the drugmaker’s discovery and development pipeline with continuous evidence synthesis and predictive modeling.
- In lab tests for acute myeloid leukemia, Co-Scientist’s repurposing ideas led researchers to several compounds that killed cancer cells at nanomolar levels, including binimetinib, which had earlier failed in Phase 2 for this disease.
- Robin guided a dry age-related macular degeneration study that surfaced two repurposed candidates, including Ripasudil and the circadian modulator KL001, which the team validated in patient-derived retinal cells.
- The developers stressed limits such as reliance on open-access data, uncertain novelty, and a difficult leap to clinical use, and DeepMind withheld Co-Scientist’s code over safety and intellectual property concerns.